Abstract
Introduction A blood-based biomarker panel to identify individuals with preclinical Alzheimer's disease (AD) would be an inexpensive and accessible first step for routine testing. Methods We analyzed 14 biomarkers that have previously been linked to AD in the Australian Imaging Biomarkers lifestyle longitudinal study of aging cohort. Results Levels of apolipoprotein J (apoJ) were higher in AD individuals compared with healthy controls at baseline and 18 months (P =.0003) and chemokine-309 (I-309) were increased in AD patients compared to mild cognitive impaired individuals over 36 months (P =.0008). Discussion These data suggest that apoJ may have potential in the context of use (COU) of AD diagnostics, I-309 may be specifically useful in the COU of identifying individuals at greatest risk for progressing toward AD. This work takes an initial step toward identifying blood biomarkers with potential use in the diagnosis and prognosis of AD and should be validated across other prospective cohorts.
| Original language | English |
|---|---|
| Pages (from-to) | 60-72 |
| Number of pages | 13 |
| Journal | Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring |
| Volume | 8 |
| DOIs | |
| State | Published - 1 Jan 2017 |
Fingerprint
Keywords
- Alzheimer's disease
- Biomarkers
- Blood
Cite this
}
Altered levels of blood proteins in Alzheimer's disease longitudinal study : Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort. / and the; AIBL Research Group.
In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 8, 01.01.2017, p. 60-72.Research output: Contribution to journal › Article
TY - JOUR
T1 - Altered levels of blood proteins in Alzheimer's disease longitudinal study
T2 - Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort
AU - and the
AU - AIBL Research Group
AU - Gupta, Veer Bala
AU - Hone, Eugene
AU - Pedrini, Steve
AU - Doecke, James
AU - O'Bryant, Sid
AU - James, Ian
AU - Bush, Ashley I.
AU - Rowe, Christopher C.
AU - Villemagne, Victor L.
AU - Ames, David
AU - Masters, Colin L.
AU - Martins, Ralph N.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Introduction A blood-based biomarker panel to identify individuals with preclinical Alzheimer's disease (AD) would be an inexpensive and accessible first step for routine testing. Methods We analyzed 14 biomarkers that have previously been linked to AD in the Australian Imaging Biomarkers lifestyle longitudinal study of aging cohort. Results Levels of apolipoprotein J (apoJ) were higher in AD individuals compared with healthy controls at baseline and 18 months (P =.0003) and chemokine-309 (I-309) were increased in AD patients compared to mild cognitive impaired individuals over 36 months (P =.0008). Discussion These data suggest that apoJ may have potential in the context of use (COU) of AD diagnostics, I-309 may be specifically useful in the COU of identifying individuals at greatest risk for progressing toward AD. This work takes an initial step toward identifying blood biomarkers with potential use in the diagnosis and prognosis of AD and should be validated across other prospective cohorts.
AB - Introduction A blood-based biomarker panel to identify individuals with preclinical Alzheimer's disease (AD) would be an inexpensive and accessible first step for routine testing. Methods We analyzed 14 biomarkers that have previously been linked to AD in the Australian Imaging Biomarkers lifestyle longitudinal study of aging cohort. Results Levels of apolipoprotein J (apoJ) were higher in AD individuals compared with healthy controls at baseline and 18 months (P =.0003) and chemokine-309 (I-309) were increased in AD patients compared to mild cognitive impaired individuals over 36 months (P =.0008). Discussion These data suggest that apoJ may have potential in the context of use (COU) of AD diagnostics, I-309 may be specifically useful in the COU of identifying individuals at greatest risk for progressing toward AD. This work takes an initial step toward identifying blood biomarkers with potential use in the diagnosis and prognosis of AD and should be validated across other prospective cohorts.
KW - Alzheimer's disease
KW - Biomarkers
KW - Blood
UR - http://www.scopus.com/inward/record.url?scp=85018739152&partnerID=8YFLogxK
U2 - 10.1016/j.dadm.2017.04.003
DO - 10.1016/j.dadm.2017.04.003
M3 - Article
AN - SCOPUS:85018739152
VL - 8
SP - 60
EP - 72
JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
SN - 2352-8729
ER -